The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning.
Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.
Looking for the S&P500 stocks that are experiencing notable gaps on Wednesday? Find out which stocks are gapping up and gapping down in the S&P500 index during today's session.
A company that generates cash isn’t automatically a winner.
Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
A number of stocks jumped in the afternoon session after the major indices popped (Nasdaq +3.4%, S&P 500 +2.5%) in response to the positive outcome of U.S.-China trade negotiations, as both sides agreed to pause some tariffs for 90 days, signaling a potential turning point in ongoing tensions. This rollback cuts U.S. tariffs on Chinese goods to 30% and Chinese tariffs on U.S. imports to 10%, giving companies breathing room to reset inventories and supply chains.
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages.
Just because a business is in the green today doesn’t mean it will thrive tomorrow.
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Agilent (NYSE:A) and its peers.
The US market is yet to commence its session on Friday, but let's get a preview of the pre-market session and explore the top S&P500 gainers and losers driving the early market movements.
Looking back on research tools & consumables stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Sotera Health Company (NASDAQ:SHC) and its peers.
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the research tools & consumables stocks, including Bruker (NASDAQ:BRKR) and its peers.
David Kostin, the Chief U.S. Equity Strategist of Goldman Sachs (NYSE: GS), has revised his earnings growth forecast, citing a weaker economic outlook, and highlighted a shift in market trends.
Life sciences tools company Agilent Technologies (NYSE:A) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 1.4% year on year to $1.68 billion. On the other hand, next quarter’s revenue guidance of $1.63 billion was less impressive, coming in 1.4% below analysts’ estimates. Its GAAP profit of $1.11 per share was in line with analysts’ consensus estimates.
